Skip to main content

Table 3 Adverse Events

From: The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005)

Adverse events in all cycles

Number of patients (%)

All grade

Grade ≥ 3

Diarrhea

57 (35.8)

6 (3.8)

Stomatitis

7 (4.4)

1 (0.6)

Hand-foot syndrome

28 (21.7)

15 (9.4)

Vomiting

7 (4.4)

0

Rash

23 (14.5)

0

Myelosuppression

15 (9.4)

9 (5.7)

Nausea

1 (0.6)

0

Peripheral neurotoxicity

10 (6.3)

0

Malaise

1 (0.6)

0